ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
The development of 2,3,7,8-tetrachlorophenothiazine as a drug lead
dc.contributor.author | Fried, Kristian Wolfgang | |
dc.date.accessioned | 2021-10-08T18:53:36Z | |
dc.date.available | 2021-10-08T18:53:36Z | |
dc.date.issued | 2007-05-31 | |
dc.identifier.uri | http://hdl.handle.net/1808/32003 | |
dc.description | Dissertation (Ph.D.)--University of Kansas, Pharmacology, Toxicology, and Therapeutics, 2007. | en_US |
dc.description.abstract | The dioxin analogue 2,3,7,8-tetrachlorophenothiazine (TCPT) was synthesized and developed as a drug lead with potential applications in chemoprevention, body weight control, type II diabetes, contraception, and longevity. These well-documented effects of dioxins are believed to be mediated through two key mechanisms of action: AhR binding with downsteam induction of enzyme activity, and reduced IGF-1 signaling. The effects of TCPT on these pathways were investigated quantitatively.TCPT showed an affinity to AhR similar to that of TCDD, and it induced EROD activity with high efficacy in vitro. Its potency regarding enzyme induction, however, was lower by two orders of magnitude compared to that of TCDD. Metabolism was demonstrated to yield low-potency derivatives.Dose-response relationships were developed for TCPT and TCDD regarding the reduction of serum IGF-1 levels in the rat. TCPT displayed in this regard also high efficacy, but very low potency compared to TCDD.Unlike TCDD, TCPT did not affect thyroid homeostasis at doses that lowered IGF-1 signaling. These findings suggest that TCPT could become a suitable drug lead. | en_US |
dc.publisher | University of Kansas | en_US |
dc.rights | This item is protected by copyright and unless otherwise specified the copyright of this thesis/dissertation is held by the author. | en_US |
dc.subject | Health and environmental sciences | en_US |
dc.subject | Chemoprevention | en_US |
dc.subject | Dioxins | en_US |
dc.subject | Tetrachlorophenothiazine | en_US |
dc.title | The development of 2,3,7,8-tetrachlorophenothiazine as a drug lead | en_US |
dc.type | Dissertation | en_US |
dc.thesis.degreeDiscipline | Pharmacology, Toxicology, and Therapeutics | |
dc.thesis.degreeLevel | Ph.D. | |
kusw.bibid | 5349196 | |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
-
Dissertations [4889]